Pandolfo M. Friedreich ataxia. In: PJ Vinken and GW Bruyn, editors. Handbook of clinical neurology. 2012;103:275–94.

Vankan P. Prevalence gradients of Friedreich’s ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge. J Neurochem. 2013;126:11–20.

Article  CAS  PubMed  Google Scholar 

Pandolfo M. Friedreich ataxia: new pathways. J Child Neurol. 2012;27:1204–11.

Article  PubMed  PubMed Central  Google Scholar 

Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307:46–9.

Article  PubMed  Google Scholar 

Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol. 2009;256:3–8.

Article  PubMed  Google Scholar 

Galea CA, Huq A, Lockhart PJ, Tai G, Corben LA, Yiu EM, et al. Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia. Ann Neurol. 2016;79:485–95.

Article  CAS  PubMed  Google Scholar 

Soragni E, Herman D, Dent SY, Gottesfeld JM, Wells RD, Napierala M. Long intronic GAA*TTC repeats induce epigenetic changes and reporter gene silencing in a molecular model of Friedreich ataxia. Nucleic Acids Res. 2008;36:6056–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anzovino A, Lane DJ, Huang ML, Richardson DR. Fixing frataxin: ‘ironing out’ the metabolic defect in Friedreich’s ataxia. Br J Pharmacol. 2014;171:2174–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lill R. Function and biogenesis of iron-sulphur proteins. Nature. 2009;460:831–8.

Article  CAS  PubMed  Google Scholar 

Perdomini M, Hick A, Puccio H, Pook MA. Animal and cellular models of Friedreich ataxia. J Neurochem. 2013;126:65–79.

Article  CAS  PubMed  Google Scholar 

Anjomani Virmouni S, Ezzatizadeh V, Sandi C, Sandi M, Al-Mahdawi S, Chutake Y, et al. A novel GAA-repeat-expansion-based mouse model of Friedreich’s ataxia. Dis Model Mech. 2015;8:225–35.

PubMed  PubMed Central  Google Scholar 

Ocana-Santero G, Diaz-Nido J, Herranz-Martin S. Future prospects of gene therapy for Friedreich’s ataxia. Int J Mol Sci. 2021;22:1815.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gerard C, Archambault AF, Bouchard C, Tremblay JP. A promising mouse model for Friedreich ataxia progressing like human patients. Behav Brain Res. 2022;436:114107.

Article  PubMed  Google Scholar 

Ouellet DL, Cherif K, Rousseau J, Tremblay JP. Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia. Gene Ther. 2017;24:265–74.

Article  CAS  PubMed  Google Scholar 

Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014;15:445–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He X, Urip BA, Zhang Z, Ngan CC, Feng B. Evolving AAV-delivered therapeutics towards ultimate cures. J Mol Med (Berl). 2021;99:593–617.

Article  PubMed  Google Scholar 

Kim E, Koo T, Park SW, Kim D, Kim K, Cho HY, et al. In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nat commun. 2017;8:14500.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 2013;31:827–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding X, Seebeck T, Feng Y, Jiang Y, Davis GD, Chen F. Improving CRISPR-Cas9 genome editing efficiency by fusion with chromatin-modulating peptides. CRISPR J. 2019;2:51–63.

Article  CAS  PubMed  Google Scholar 

Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42:e168.

Article  PubMed  PubMed Central  Google Scholar 

Mazzara PG, Muggeo S, Luoni M, Massimino L, Zaghi M, Valverde PT, et al. Frataxin gene editing rescues Friedreich’s ataxia pathology in dorsal root ganglia organoid-derived sensory neurons. Nat Commun. 2020;11:4178.

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Polak U, Bhalla AD, Rozwadowska N, Butler JS, Lynch DR, et al. Excision of Expanded GAA Repeats Alleviates the Molecular Phenotype of Friedreich’s Ataxia. Mol Ther. 2015;23:1055–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Rozwadowska N, Clark A, Fil D, Napierala JS, Napierala M. Excision of the expanded GAA repeats corrects cardiomyopathy phenotypes of iPSC-derived Friedreich’s ataxia cardiomyocytes. Stem Cell Res. 2019;40:101529.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Li J, Wang J, Zhang S, Giles K, Prakash TP, et al. Premature transcription termination at the expanded GAA repeats and aberrant alternative polyadenylation contributes to the Frataxin transcriptional deficit in Friedreich’s ataxia. Hum Mol Genet. 2022;31:3539–57.

Article  PubMed  PubMed Central  Google Scholar 

Sivakumar A, Cherqui S. Advantages and limitations of gene therapy and gene editing for Friedreich’s ataxia. Front Genome Ed. 2022;4:903139.

Article  PubMed  PubMed Central  Google Scholar 

Rocca CJ, Rainaldi JN, Sharma J, Shi Y, Haquang JH, Luebeck J, et al. CRISPR-Cas9 gene editing of hematopoietic stem cells from patients with Friedreich’s ataxia. Mol Ther Methods Clin Dev. 2020;17:1026–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Belbellaa B, Reutenauer L, Monassier L, Puccio H. Correction of half the cardiomyocytes fully rescue Friedreich ataxia mitochondrial cardiomyopathy through cell-autonomous mechanisms. Hum Mol Genet. 2019;28:1274–85.

Article  CAS  PubMed  Google Scholar 

Belbellaa B, Reutenauer L, Messaddeq N, Monassier L, Puccio H. High levels of Frataxin overexpression lead to mitochondrial and cardiac toxicity in mouse models. Mol Ther Methods Clin Dev. 2020;19:120–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li L, Matsui M, Corey DR. Activating frataxin expression by repeat-targeted nucleic acids. Nat commun. 2016;7:10606.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greene E, Mahishi L, Entezam A, Kumari D, Usdin K. Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res. 2007;35:3383–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li K, Singh A, Crooks DR, Dai X, Cong Z, Pan L, et al. Expression of human frataxin is regulated by transcription factors SRF and TFAP2. PLoS One. 2010;5:e12286.

Article  PubMed  PubMed Central  Google Scholar 

Yameogo P, Duchene BL, Majeau N, Tremblay JP. CRISPR-SCReT (CRISPR-Stop Codon Read Through) method to control Cas9 expression for gene editing. Gene Ther. 2022;29:171–7.

Yamada M, Watanabe Y, Gootenberg JS, Hirano H, Ran FA, Nakane T, et al. Crystal structure of the minimal Cas9 from campylobacter jejuni reveals the molecular diversity in the CRISPR-Cas9 Systems. Mol Cell. 2017;65:1109–21.

Article  CAS  PubMed  Google Scholar 

Silva-Pinheiro P, Cerutti R, Luna-Sanchez M, Zeviani M, Viscomi C. A single intravenous injection of AAV-PHP.B-hNDUFS4 ameliorates the phenotype of Ndufs4 (−/−) Mice. Mol Ther Methods Clin Dev. 2020;17:1071–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chapdelaine P, Gerard C, Sanchez N, Cherif K, Rousseau J, Ouellet DL, et al. Development of an AAV9 coding for a 3XFLAG-TALEfrat#8-VP64 able to increase in vivo the human frataxin in YG8R mice. Gene Ther. 2016;23:606–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tabebordbar M, Lagerborg KA, Stanton A, King EM, Ye S, Tellez L, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell. 2021;184:4919–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rocca CJ, Goodman SM, Dulin JN, Haquang JH, Gertsman I, Blondelle J, et al. Transplantation of wild-type mouse hematopoietic stem and progenitor cells ameliorates deficits in a mouse model of Friedreich’s ataxia. Sci Transl Med. 2017;9:eaaj2347.

Article  PubMed  PubMed Central